(HOLX) Hologic - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4364401012

Diagnostics, Imaging, Surgical, Skeletal

Health Care Equipment
Market Cap in USD: 16,701m

IPO / Inception: 1990-06-21
12m vs SPY: -9.40%

EPS (Earnings per Share)

EPS CAGR: -15.97%
EPS Trend: -39.9%

Last SUE: 1.57
Qual. Beats: 2

Revenue

Rev. CAGR: -8.61%
Rev. Trend: -50.2%

Last SUE: 1.79
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	2.85%
Value at Risk 5%th	4.38%
Relative Tail Risk	-6.58%

Reward TTM
Sharpe Ratio	0.24
Alpha	-1.98
CAGR/Max DD	-0.04

Character TTM
Hurst Exponent	0.311
Beta	0.300
Beta Downside	0.291

Drawdowns 3y
Max DD	39.85%
Mean DD	16.12%
Median DD	15.15%

Description: HOLX Hologic January 02, 2026

Hologic Inc. (NASDAQ: HOLX) develops, manufactures, and distributes diagnostics, medical imaging, and surgical solutions focused on women’s health, operating through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

The Diagnostics line includes Aptima molecular assays for infectious diseases (e.g., Hepatitis B/C, HIV, CMV), bacterial vaginosis and candida, as well as SARS-CoV-2 tests; the Breast Health portfolio offers 3-D digital mammography, image-analysis software, and minimally invasive biopsy guidance; GYN Surgical products feature the MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation, and the CoolSeal bipolar vessel sealing devices; Skeletal Health is anchored by the Horizon DXA dual-energy X-ray absorptiometry system.

In FY 2024 Hologic reported $7.9 billion in revenue, with the Diagnostics segment contributing roughly 45 % and posting a 9 % YoY growth rate driven by increased demand for molecular testing post-pandemic. The Breast Health segment remains the most profitable, delivering a 22 % operating margin, while the GYN Surgical line is expanding as minimally invasive procedures gain market share. Key macro drivers include an aging female population, rising prevalence of breast and gynecologic cancers, and favorable reimbursement trends for high-value diagnostic and image-guided procedures.

For a deeper, data-driven assessment of HOLX’s valuation and risk profile, you may find the analyst tools on ValueRay useful.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (565.8m TTM) > 0 and > 6% of Revenue (6% = 246.0m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA -2.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 65.63% (prev 69.13%; Δ -3.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.06b > Net Income 565.8m (YES >=105%, WARN >=100%)

Net Debt (667.3m) to EBITDA (1.08b) ratio: 0.62 <= 3.0 (WARN <= 3.5)

Current Ratio 3.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (225.7m) change vs 12m ago -4.34% (target <= -2.0% for YES)

Gross Margin 53.01% (prev 55.78%; Δ -2.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.13% (prev 44.02%; Δ 1.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.95 (EBITDA TTM 1.08b / Interest Expense TTM 98.1m) >= 6 (WARN >= 3)

Altman Z'' 4.65

(A) 0.30 = (Total Current Assets 3.67b - Total Current Liabilities 977.2m) / Total Assets 9.01b

(B) 0.38 = Retained Earnings (Balance) 3.41b / Total Assets 9.01b

(D) 0.84 = Book Value of Equity 3.31b / Total Liabilities 3.97b

Total Rating: 4.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 62.46

1. Piotroski 6.0pt

2. FCF Yield 5.41%

3. FCF Margin 22.60%

4. Debt/Equity 0.52

5. Debt/Ebitda 0.62

6. ROIC - WACC (= 2.65)%

7. RoE 11.74%

8. Rev. Trend -50.22%

9. EPS Trend -39.93%

What is the price of HOLX shares?

As of January 17, 2026, the stock is trading at USD 75.16 with a total of 3,490,689 shares traded.
Over the past week, the price has changed by +0.15%, over one month by -0.05%, over three months by +9.46% and over the past year by +7.16%.

Is HOLX a buy, sell or hold?

Hologic has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold HOLX.

Strong Buy: 3
Buy: 3
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the HOLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	76.4	1.7%
Analysts Target Price	76.4	1.7%
ValueRay Target Price	75.8	0.9%

HOLX Fundamental Data Overview January 15, 2026

P/E Trailing = 30.0683
P/E Forward = 16.3934
P/S = 4.0729
P/B = 3.308
P/EG = 1.6546
Revenue TTM = 4.10b USD
EBIT TTM = 779.5m USD
EBITDA TTM = 1.08b USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 33.4m USD (from shortTermDebt, last quarter)
Debt = 2.63b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 667.3m USD (from netDebt column, last quarter)
Enterprise Value = 17.13b USD (16.70b + Debt 2.63b - CCE 2.20b)
Interest Coverage Ratio = 7.95 (Ebit TTM 779.5m / Interest Expense TTM 98.1m)
EV/FCF = 18.48x (Enterprise Value 17.13b / FCF TTM 926.7m)
FCF Yield = 5.41% (FCF TTM 926.7m / Enterprise Value 17.13b)
FCF Margin = 22.60% (FCF TTM 926.7m / Revenue TTM 4.10b)
Net Margin = 13.80% (Net Income TTM 565.8m / Revenue TTM 4.10b)
Gross Margin = 53.01% ((Revenue TTM 4.10b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 60.90% (prev 56.32%)
Tobins Q-Ratio = 1.90 (Enterprise Value 17.13b / Total Assets 9.01b)
Interest Expense / Debt = 0.37% (Interest Expense 9.60m / Debt 2.63b)
Taxrate = 17.63% (40.1m / 227.4m)
NOPAT = 642.0m (EBIT 779.5m * (1 - 17.63%))
Current Ratio = 3.75 (Total Current Assets 3.67b / Total Current Liabilities 977.2m)
Debt / Equity = 0.52 (Debt 2.63b / totalStockholderEquity, last quarter 5.05b)
Debt / EBITDA = 0.62 (Net Debt 667.3m / EBITDA 1.08b)
Debt / FCF = 0.72 (Net Debt 667.3m / FCF TTM 926.7m)
Total Stockholder Equity = 4.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.23% (Net Income 565.8m / Total Assets 9.01b)
RoE = 11.74% (Net Income TTM 565.8m / Total Stockholder Equity 4.82b)
RoCE = 10.64% (EBIT 779.5m / Capital Employed (Equity 4.82b + L.T.Debt 2.50b))
RoIC = 8.75% (NOPAT 642.0m / Invested Capital 7.34b)
WACC = 6.11% (E(16.70b)/V(19.33b) * Re(7.02%) + D(2.63b)/V(19.33b) * Rd(0.37%) * (1-Tc(0.18)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.06%
[DCF Debug] Terminal Value 84.13% ; FCFF base≈1.02b ; Y1≈903.7m ; Y5≈754.0m
Fair Price DCF = 92.86 (EV 21.38b - Net Debt 667.3m = Equity 20.71b / Shares 223.1m; r=6.11% [WACC]; 5y FCF grow -13.82% → 2.90% )
EPS Correlation: -39.93 | EPS CAGR: -15.97% | SUE: 1.57 | # QB: 2
Revenue Correlation: -50.22 | Revenue CAGR: -8.61% | SUE: 1.79 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.10 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=11
EPS current Year (2026-09-30): EPS=4.56 | Chg30d=-0.004 | Revisions Net=-2 | Growth EPS=+6.9% | Growth Revenue=+4.5%
EPS next Year (2027-09-30): EPS=5.00 | Chg30d=-0.001 | Revisions Net=-1 | Growth EPS=+9.7% | Growth Revenue=+5.3%

Additional Sources for HOLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle